Literature DB >> 14573325

Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis.

Paolo Verdecchia1, Fabio Angeli, Claudia Borgioni, Roberto Gattobigio, Gianni de Simone, Richard B Devereux, Carlo Porcellati.   

Abstract

BACKGROUND: Some studies have suggested that serial changes in left ventricular (LV) mass in hypertensive subjects predict the subsequent risk of cardiovascular disease. The aim of this meta-analysis was to evaluate the prognostic impact of LV hypertrophy regression in hypertension.
METHODS: We undertook a meta-analysis of studies that reported echocardiographic LV mass before and during antihypertensive therapy, with subsequent assessment of cardiovascular events. The aims of this meta-analysis were: 1) to compare subjects with LV hypertrophy (LVH) during treatment (persistence or new development of LVH) with those with LVH at baseline, but not during treatment (regression of LVH); and 2) to compare subjects with LVH at baseline, but not during treatment with those without LVH both before and during treatment (regression of LVH versus persistently normal LV mass).
RESULTS: The four eligible studies included 1064 hypertensive subjects (41% women) aged 45 to 51 years who repeated the echocardiographic study 3 to 10 years after the initial examination. The definition of LVH was based on a LV mass corrected by body surface area >125 g/m(2) in two studies and >110 g/m(2) (for women) and 124 g/m(2) (for men) in two studies. Compared with subjects with lack of regression or new development of LVH, those with LVH regression showed a reduced risk of subsequent cardiovascular disease (odds ratio 0.41, 95% CI 0.21 to 0.78, P =.007). Compared with subjects with regression of LVH, those with persistently normal LV mass showed a similar risk of subsequent events (odds ratio 0.64, 95% CI = 0.31 to 1.30, P =.21).
CONCLUSION: Compared with persistence or new development of LV hypertrophy, regression of LV hypertrophy during antihypertensive treatment is associated with a marked reduction in risk for subsequent cardiovascular disease.

Entities:  

Mesh:

Year:  2003        PMID: 14573325     DOI: 10.1016/s0895-7061(03)01018-5

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  62 in total

Review 1.  Left ventricular hypertrophy in hypertension: its arrhythmogenic potential.

Authors:  Thomas Kahan; Lennart Bergfeldt
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

Review 2.  Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.

Authors:  Cam Patterson; Andrea L Portbury; Jonathan C Schisler; Monte S Willis
Journal:  Circ Res       Date:  2011-08-05       Impact factor: 17.367

3.  Newly proposed electrocardiographic criteria for the diagnosis of left ventricular hypertrophy in a Chinese population.

Authors:  Qingmiao Shao; Lei Meng; Gary Tse; Abhishek C Sawant; Calista Zhuo Yi Chan; George Bazoukis; Adrian Baranchuk; Guangping Li; Tong Liu
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-10-03       Impact factor: 1.468

Review 4.  Evidence for distinct effects of exercise in different cardiac hypertrophic disorders.

Authors:  Emily J Johnson; Brad P Dieter; Susan A Marsh
Journal:  Life Sci       Date:  2015-01-26       Impact factor: 5.037

5.  Diagnostic performance of electrocardiographic criteria for left ventricular hypertrophy among various body mass index groups compared to diagnosis by cardiac magnetic resonance imaging.

Authors:  Veerawat Nomsawadi; Rungroj Krittayaphong
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-02-05       Impact factor: 1.468

Review 6.  Myocardial remodeling in hypertension.

Authors:  W Nadruz
Journal:  J Hum Hypertens       Date:  2014-05-08       Impact factor: 3.012

Review 7.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

8.  Abnormal cardiac structure and function in the metabolic syndrome: a population-based study.

Authors:  Bilal Aijaz; Khawaja A Ammar; Francisco Lopez-Jimenez; Margaret M Redfield; Steven J Jacobsen; Richard J Rodeheffer
Journal:  Mayo Clin Proc       Date:  2008-12       Impact factor: 7.616

Review 9.  Endothelial dysfunction as a target for prevention of cardiovascular disease.

Authors:  Daniele Versari; Elena Daghini; Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 10.  Hypertension and Diabetes: what are the pros to treating early surrogates?

Authors:  Roland E Schmieder
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.